 |
市場調查報告書
商品編碼
2148400
急性骨髓性白血病治療市場：依疾病、療法、給藥途徑、最終用戶和地區分類Acute Myeloid Leukemia Therapeutics Market, By Disease Type, By Treatment Type, By Route of Administration, By End User, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，急性骨髓性白血病)治療市場規模將達到 37.6 億美元，到 2033 年將達到 72.3 億美元。預計 2026 年至 2033 年的複合年成長率將達到 9.8%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 37.6億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 9.80% | 2033年市場規模預測： | 72.3億美元 |
急性骨髓性白血病（AML）是一種致命的血液癌症，起源於骨髓。在這種疾病中，未成熟的髓系細胞不受控制地增殖，干擾正常血球的生成。由於其分子異質性以及與多種基因突變的關聯，AML是一種複雜的疾病，需要更專業的治療策略。
急性骨髓性白血病)的治療格局正從化療轉向標靶治療、免疫療法和精準醫療，FLT3、IDH1/2、BCL-2 和 menin 抑制劑的出現拓寬了治療選擇。全球急性骨髓性白血病治療市場的主要促進因素包括疾病負擔的加重、臨床研究的發展、對新療法的投資。
市場動態
全球急性骨髓性白血病( AML) 治療市場正受到以下因素的推動：老齡化社會中 AML 盛行率的上升、基因組分析技術的進步以及突變特異性標靶治療的廣泛應用。此外，快速法規核准流程的引入促進了新療法的研發和商業化，而醫療保健領域投入的增加也提高了患者獲得尖端癌症治療的機會。
然而，急性骨髓性白血病治療市場的成長受到許多因素的限制，例如治療費用高昂、分子複雜性、抗藥性和疾病復發。儘管如此，不斷擴充的研發管線仍蘊藏著巨大的機遇，包括menin抑制劑、抗體藥物複合體（ADC）、雙特異性抗體、CAR-T療法和新型聯合治療。
本次調查的主要特點
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球急性骨髓性白血病治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使行銷負責人和企業經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份《全球急性骨髓性白血病治療市場》報告旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用分析全球急性骨髓性白血病治療市場中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特的分析
- 市場機遇
- 產業趨勢
第4章 全球急性骨髓性白血病治療市場：依疾病類型分類，2021-2033年
- 髓母細胞白血病
- 早幼粒細胞白血病
- 骨髓單核細胞白血病
- 單核細胞白血病
- 其他
第5章 全球急性骨髓性白血病治療市場：依治療類型分類，2021-2033年
- 化療
- 標靶治療
- 免疫療法
- 聯合治療
- 支持性護理
第6章 全球急性骨髓性白血病治療市場：依給藥途徑分類，2021-2033年
- 腸外
- 口服
第7章 全球急性骨髓性白血病治療市場：依最終用戶分類，2021-2033年
- 醫院
- 專業腫瘤中心
- 診所及門診醫療中心
- 居家照護環境
- 其他
第8章 全球急性骨髓性白血病治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第9章 競爭情勢
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol Myers Squibb Company
- Daiichi Sankyo Company, Limited
- Jazz Pharmaceuticals plc
- Novartis AG
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Rigel Pharmaceuticals, Inc.
- Servier Pharmaceuticals LLC
第10章 分析師建議
- 機會分析
- 分析師意見
- Coherent Opportunity Map
第11章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI10071
Acute Myeloid Leukemia Therapeutics Market is estimated to be valued at USD 3.76 Bn in 2026 and is expected to reach USD 7.23 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.76 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 7.23 Bn |
Acute Myeloid Leukemia (AML) is a lethal blood cancer that arises in the bone marrow. It is an uncontrolled growth of immature myeloid cells with interference to the normal blood cell production. The molecular heterogeneity and association with multiple genetic alterations makes AML a complex disease requiring more specialized treatment strategies.
The acute myeloid leukemia treatment landscape has moved from chemotherapy to targeted therapy, immunotherapies and precision-based therapies, with the addition of FLT3, IDH1/2, BCL-2 and menin inhibitors broadening the treatment options. Key drivers for the global acute myeloid leukemia therapeutics market include the rising burden of the disease, clinical research, and investment in new therapies.
Market Dynamics
The global acute myeloid leukemia therapeutics market is driven by the increasing prevalence of AM acute myeloid leukemia in aging populations, advancements in genomic profiling, and the enhanced application of mutation-specific targeted therapy. Moreover, expedited regulatory pathways are enabling the development and commercialization of new treatments, and greater healthcare investment is improving the access to cutting-edge oncology care.
However, the growth of acute myeloid leukemia therapeutics market is limited by factors such as high treatment cost, molecular complexity, resistance to drugs and the recurrence of the disease. Nevertheless, significant opportunities exist in growing pipeline of menin inhibitors, antibody-drug conjugates, bispecific antibodies, CAR-T therapies and new combination regimens.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acute myeloid leukemia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Rigel Pharmaceuticals, Inc., and Servier Pharmaceuticals LLC
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global acute myeloid leukemia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute myeloid leukemia therapeutics market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Myeloblastic Leukemia
- Promyelocytic Leukemia
- Myelomonocytic Leukemia
- Monocytic Leukemia
- Others
- Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Combination Therapy
- Supportive Care
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Parenteral
- Oral
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Oncology Centers
- Clinics and Ambulatory Care Centers
- Homecare Settings
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol Myers Squibb Company
- Daiichi Sankyo Company, Limited
- Jazz Pharmaceuticals plc
- Novartis AG
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Rigel Pharmaceuticals, Inc.
- Servier Pharmaceuticals LLC
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Acute Myeloid Leukemia Therapeutics Market, By Disease Type
- Global Acute Myeloid Leukemia Therapeutics Market, By Treatment Type
- Global Acute Myeloid Leukemia Therapeutics Market, By Route of Administration
- Global Acute Myeloid Leukemia Therapeutics Market, By End User
- Global Acute Myeloid Leukemia Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Industry Trends
4. Global Acute Myeloid Leukemia Therapeutics Market, By Disease Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Myeloblastic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Promyelocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Myelomonocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Monocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Acute Myeloid Leukemia Therapeutics Market, By Treatment Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Supportive Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Acute Myeloid Leukemia Therapeutics Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Acute Myeloid Leukemia Therapeutics Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinics and Ambulatory Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Acute Myeloid Leukemia Therapeutics Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Jazz Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rigel Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Servier Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
急性骨髓性白血病治療市場－2026-2032年全球市場預測
急性骨髓性白血病（AML）：市場展望、流行病學、競爭格局、市場預測報告（2026-2036年）急性骨髓性白血病（AML）：全球市場展望、流行病學、競爭格局與市場預測報告（32個主要市場），2026-2036年
急性骨髓性白血病市場分析及預測（至2035年）：類型、產品類型、技術、應用、最終用戶、功能、治療方法、疾病階段
2026-2034年急性骨髓性白血病治療藥物全球市場規模、佔有率、趨勢和成長分析報告
急性骨髓性白血病市場－全球產業規模、佔有率、趨勢、機會和預測，依化療、地區和競爭格局分類，2020-2030年預測
急性骨髓性白血病治療市場規模、佔有率、趨勢分析報告：按疾病、治療、給藥途徑、最終用途、地區和細分市場進行預測，2025 年至 2030 年